Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Arbaclofen in fragile X syndrome: results of phase 3 trials.
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
View in:
PubMed
subject areas
Aged
Aged, 80 and over
Anemia
Dose-Response Relationship, Drug
Epoetin Alfa
Erythropoietin
Female
Heart Failure
Hematinics
Hemoglobins
Humans
Male
Middle Aged
Myocardial Infarction
Proportional Hazards Models
Recombinant Proteins
Renal Insufficiency, Chronic
Risk Factors
Stroke
Treatment Outcome
authors with profiles
Ajaypal Singh